Lantheus Holdings Inc (LNTH) reports a 4% revenue increase amidst competitive pressures and strategic advancements in its product portfolio.

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and ...

Lantheus Holdings Inc. will report fourth-quarter and full-year 2025 results Thursday before the market opens, a closely watched release as investors assess whether competitive pressure on its ...

Kahn Swick & Foti, LLC recently opened an investigation into Lantheus Holdings over revenue weakness and lowered guidance for its key imaging agent Pylarify, alongside existing securities litigation ...

Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection. The Food and Drug Administration (FDA) ...

Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, ...

Lantheus (LNTH) Holdings notes that the Centers for Medicare & Medicaid Services recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare ...

(RTTNews) - Lantheus Holdings Inc. (LNTH) and GE HealthCare (GEHC) announced an exclusive licensing agreement under which GE HealthCare will develop, manufacture, and commercialize Lantheus' ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected ...